Clinical Trials Directory

Trials / Completed

CompletedNCT06111872

Ketamine-midazolam as a Sedative Agent in Endoscopic Retrograde Cholangiopancreatography.

Combination Use of Intravenous Ketamine-midazolam as a Sedative Agent in Endoscopic Retrograde Cholangiopancreatography ; A Randomized Control Trial

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
90 (actual)
Sponsor
National University of Malaysia · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Does Ketamine-Midazolam have a better efficacy and safety profile compared to Midazolam - Pethidine in Endoscopic Retrograde Cholangiopancreatography (ERCP)?

Detailed description

Ketamine- Midazolom is more efficacious in producing desired sedative state and have a better safety profile as a sedative agent in ERCP compared to Midazolam- Pethidine. The usage of sedative agent in ERCP depends on surgeon's preferences and availability of the drugs. The most commonly used sedatives in ERCP is Midazolam with pethidine. The use of Midazolam , however, is related to: 1. 20-45% failure of sedation during ERCP 2. Cardio-respiratory depression - apnoea: 15.4%, hypotension: 15.7%, bradycardia: 6.8% Due to the proven efficacy and safety profile of ketamine-midazolam as a sedative agent in procedural sedation, the investigators propose that the use of ketamine-midazolam as a sedative agent in ERCP is more effective and better safety profile when compared to Midazolam- Pethidine. The synergistic effect means to reduce the total dose of midazolam used.

Conditions

Interventions

TypeNameDescription
DRUGKetamineAdministration described in arm/ group description
DRUGMidazolamAdministration described in arm/ group description
DRUGPethidinAdministration described in arm/ group description

Timeline

Start date
2023-07-18
Primary completion
2024-02-27
Completion
2024-10-25
First posted
2023-11-01
Last updated
2025-03-25

Locations

1 site across 1 country: Malaysia

Source: ClinicalTrials.gov record NCT06111872. Inclusion in this directory is not an endorsement.